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ABSTRACT
Data on treatment glucocorticoid‐induced osteoporosis (GIO) in men are scarce. We performed a randomized, open‐label trial in men
who have taken glucocorticoids (GC) for3 months, and had an areal bone mineral density (aBMD) T‐score –1.5 standard deviations.
Subjects received 20mg/d teriparatide (n¼ 45) or 35mg/week risedronate (n¼ 47) for 18 months. Primary objective was to compare
lumbar spine (L1–L3) BMD measured by quantitative computed tomography (QCT). Secondary outcomes included BMD and
microstructure measured by high‐resolution QCT (HRQCT) at the 12th thoracic vertebra, biomechanical effects for axial compression,
anterior bending, and axial torsion evaluated by ﬁnite element (FE) analysis from HRQCT data, aBMD by dual X‐ray absorptiometry,
biochemical markers, and safety. Computed tomography scans were performed at 0, 6, and 18 months. A mixed model repeated
measures analysis was performed to compare changes from baseline between groups. Mean age was 56.3 years. Median GC dose and
duration were 8.8mg/d and 6.4 years, respectively; 39.1% of subjects had a prevalent fracture, and 32.6% received prior bisphosphonate
treatment. At 18 months, trabecular BMD had signiﬁcantly increased for both treatments, with signiﬁcantly greater increases with
teriparatide (16.3% versus 3.8%; p¼ 0.004). HRQCT trabecular and cortical variables signiﬁcantly increased for both treatments with
signiﬁcantly larger improvements for teriparatide for integral and trabecular BMD and bone surface to volume ratio (BS/BV) as a
microstructural measure. Vertebral strength increases at 18 months were signiﬁcant in both groups (teriparatide: 26.0% to 34.0%;
risedronate: 4.2% to 6.7%), with signiﬁcantly higher increases in the teriparatide group for all loadingmodes (0.005< p< 0.015). Adverse
eventswere similar between groups. None of the patients on teriparatide but ﬁve (10.6%) on risedronate developed new clinical fractures
(p¼ 0.056). In conclusion, in this 18‐month trial inmenwith GIO, teriparatide showed larger improvements in spinal BMD,microstructure,
and FE‐derived strength than risedronate. © 2013 American Society for Bone and Mineral Research.
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Introduction
Glucocorticoids (GCs) are widely prescribed for the treatmentof inﬂammatory, autoimmune, and allergic disorders. It has
been estimated that approximately 0.2% to 0.5% of the general
population is receiving GCs.(1) However, their chronic use is the
most common cause of secondary osteoporosis. A consequence
of glucocorticoid‐induced osteoporosis (GIO) is bone fragility
and an increased risk for low‐trauma fractures(2) that are
frequently the presenting manifestations of this disorder.
Fractures have been reported in 30% to 50% of patients
receiving long‐term GC therapy.(3,4) Importantly, the fracture risk
was shown to be higher in patients with GIO than in patients with
postmenopausal osteoporosis for the same level of areal bone
mineral density (aBMD)(5) measured by dual X‐ray absorptiome-
try (DXA), probably because of the additional effects of muscle
weakness and frailty, and changes in bone material properties
that are not captured by aBMD. The classical measurement of
aBMD by DXA has the disadvantage of being based on a two‐
dimensional (2D) image of a three‐dimensional (3D) structure,
which reveals no information on the depth of the bone and does
not distinguish trabecular and cortical bone. Thus, the reported
improvements in aBMD with osteoporosis therapies, although
clinically useful, do not necessarily reﬂect an accurate estimate of
restored volumetric bone mineral density (BMD) or bone
strength in patients with GIO.
Due to GCs’ primary effect of a profound inhibition of
osteoblastic bone forming activity, a need exists for therapies
that can substantially improve bone formation and the micro-
architecture status of patients with GIO. Along with such
therapies, more sensitive diagnostic and evaluation methods
beyond DXA, such as quantitative computed tomography (QCT)
or assessment of cancellous microstructure with either high‐
resolution QCT (HRQCT)(6–8) or magnetic resonance imaging
(MRI) techniques should be applied.(9) Moreover, vertebral bone
strength as the most important determinant of fracture risk can
be assessed in vivo by a simulated mechanical test based on the
BMD distribution using ﬁnite element (FE) analysis.(10) Both QCT
and HRQCT permit the separate measurement of trabecular and
cortical BMD, the latter offeringmore accurate results on cortical
and trabecular microstructure but at the expense of a higher
radiation dose (1–2 mSv for QCT of L1–L3, and 2–3 mSv for
HRQCT of T12). QCT has long been used to assess vertebral
fracture risk, to measure age‐related bone loss, and in follow‐up
of osteoporosis and other metabolic bone diseases. The validity
of this technique for measurement of vertebral cancellous bone
is widely accepted.(11) Evaluations of BMD by QCT or HRQCT
have recently been reported in the assessment of the effects of
full‐length human parathyroid hormone (PTH[1–84]) and
teriparatide in postmenopausal women with osteoporosis(7,12–
16) or with GIO,(17) as well as in men with osteoporosis.(18)
However, there are no randomized controlled studies on
treatment of GIO in men using these technologies. Moreover,
the effects of the different therapies for GIO in men have been
poorly studied.(19)
The primary objective of this study was to test the hypothesis
that teriparatide, a bone‐forming drug, was superior to
risedronate, a pyridinyl bisphosphonate that reduces bone
turnover, in improving lumbar spine BMDmeasured by QCT over
18 months in males with GIO. Furthermore, we compared the
treatment effects of both drugs using recently developed
imaging techniques, such as BMD and microstructure measured
by HRQCT, and vertebral body strength computed by HRQCT‐
based nonlinear FE analysis.
Patients and Methods
Study design
Patients at 16 centers in Germany, Greece, Italy, and Spain were
enrolled in this phase 3, randomized, open‐label, active
comparator controlled study, which was conducted between
July 2007 and October 2010. The study consisted of two study
periods: a screening phase of up to 6 weeks, and an 18‐month
open‐label treatment phase. At the baseline visit, patients were
randomized in a 1:1 ratio to either 20 µg teriparatide once a day
as a subcutaneous injection or 35mg risedronate once weekly
orally as tablet. Randomization was done centrally and stratiﬁed
by previous bisphosphonate use; ie, whether the patient used
bisphosphonates for a total of at least 1 month at any time prior
to study entry. Any previous osteoporosis treatment given at the
time of screening was discontinued before randomization and
for the duration of the study. After randomization, patients
received the study medication for 18 months, with clinical visits
occurring after 3, 6, 12, and 18 months. All patients were to
concomitantly receive 1 g elemental calcium and 800 to 1200 IU
of vitamin D per day during the study.
The study was approved by the responsible institutional
review boards at each center, and was conducted in accordance
with the ethical principles of the Declaration of Helsinki, good
clinical practices, and applicable laws and regulations. The
patients’ written informed consent had been obtained before
conducting any study procedures.
Participants
Male ambulatory outpatients aged 25 years with normal
laboratory values for serum calcium, alkaline phosphatase, 25‐
hydroxyvitaminD, and PTHwere enrolled. They had a lumbar spine
(L1–L4), femoral neck, or total hip BMD T‐score of at least 1.5 SDs
below the corresponding normal young adult man average BMD.
For inclusion, at least two lumbar vertebrae were required to be
without imaging artifacts, fractures, or other abnormalities that
would interfere with the DXA and QCT assessments. Subjects had
to have receivedGC therapy at an average doseof at least 5.0mg/d
of prednisone or its equivalent for a minimum of 3 consecutive
months immediately preceding the screening visit. Exclusion
criteria included presence of skeletal diseases other than GIO,
prevalent spinal fractures at both the 12th thoracic vertebra (T12)
and L1, impaired renal function (creatinine clearance<30mL/min),
abnormal thyroid function not corrected by therapy, history of
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symptomatic nephrolithiasis or urolithiasis in the year prior to
randomization, malignant neoplasms in the 5 years prior to
randomization, and any contraindication to therapy with teripara-
tide or risedronate. Patients were also excluded if they had taken
intravenous bisphosphonates within 12 months prior to the
screening visit, or strontium ranelate or ﬂuoride at therapeutic
doses (20mg/d) for more than 3 months in the 2 years prior to
randomization, or for more than a total of 2 years, or at any dose
within the 6months prior to randomization. Previous treatment for
any duration with calcitonin, oral bisphosphonates, or active
vitamin D3 analogues that had been stopped prior to or at the
randomization visit was allowed.
Efficacy measures
QCT and HRQCT scans were obtained at months 0, 6, and 18. The
primary endpoint in the EuroGIOPs trial was the change in
trabecular BMD (Tb.BMD) of L1–L3 at month18; its measurement
at 6 months was a secondary endpoint. Further secondary
efﬁcacy endpoints included HRQCT variables, strength (failure
load) and stiffness at T12 as estimated by FE analysis, aBMD of the
lumbar spine, total hip, and femoral neck measured by DXA, and
biochemical markers of bone turnover including serum amino‐
terminal propeptide of type I procollagen (P1NP) and serum beta
C‐terminal cross‐linking telopeptide of type I collagen (b‐CTx).
Assessment methods for efficacy measures
The efﬁcacy endpoints of this trial were evaluated by trained
experts at a central imaging laboratory in Kiel, Germany, using
validated image analysis software for QCT and HRQCT; by trained
experts at an engineering laboratory in Vienna, Austria, for FE
analysis; by a central reading center for DXA analysis and quality
assurance (BioImaging Technologies, Leiden, The Netherlands);
and by a central laboratory for serum analytics (Covance, Geneva,
Switzerland). All central facilities, as well as the personnel at the
local radiology departments of the study sites, were blinded to
treatment assignment.
QCT imaging and analysis
To assess Tb.BMD, a continuous spiral computed tomography
(CT) covering all of L1–L3 was acquired at 120 kV and 100mA. The
slice thickness was 3mm; pixel size was in the order of 0.6mm,
but could vary between clinical sites. Quality assurance and BMD
calibration were carried out using the dedicated phantoms and
procedures provided byMindways, Inc. (Austin, TX, USA). All scans
were centrally evaluated in a volume of interest (VOI) with an
elliptical cross‐section (Fig. 1E) with the software QCTPRO version
4.1.3 (Mindways, Inc.) following the guidelines of the manufac-
turer. This included calibration and ﬁeld uniformity correction
measures using two phantoms provided by Mindways, Inc. Tb.
BMDwas calculated for each vertebra and also as an average of all
lumbar vertebraemeasured. Vertebrae judged as fractured by the
central radiologist were not included in the analysis.
HRQCT imaging and analysis
For HRQCT, a thin‐slice spiral CT scan of T12 was acquired at
120 kV and 360mA. If there was a fracture in T12, the HRQCT was
performed on an intact L1 vertebra. The images were density‐
calibrated using the same phantoms and methods as for QCT.
Technical details of the procedure have recently been pub-
lished.(20) The complete vertebral body was segmented using a
semiautomatic algorithm of the software tool StructuralIn-
sight.(7,20) HRQCT permits visualization of the 3D trabecular
microstructure, although partial volume effects lead to depiction
as a coarser structure (Fig. 1A–D). Compared to QCT, a sharper
delineation of the cortical contours can be achieved (Fig. 1E
versus F), which also permits differentiation of thicker and
thinner or porous endplates (Fig. 1, top row). The inner contour of
the cortex was deﬁned using a combination of active shape, and
global and local thresholding (Fig. 1G, H). The ﬁnal contours of
the cortex could be modiﬁed in 3D by the user if the automated
procedure did not produce satisfactory results. Bone density of
the bone compartment has been referred to as tissue mineral
density (TMD).(21) Because we cannot resolve cortical pores, TMD
will be affected by mineral density of pure bone matrix and
porosity. Moreover, because the endosteal cortical‐trabecular
transition is gradual, the cortical region may include some
endosteal marrow space, and thus we conservatively refer to the
density in the cortical region as cortical BMD (Ct.BMD), not TMD.
As microstructural measure for the cortex, apparent cortical
thickness (app.Ct.Th) was assessed directly in 3D using an
adaptation of an algorithm reported by Krebs and colleagues.(8)
An additional measure of cortical thickness was derived, this one
weighted by local cortical BMD relative to an assumed full
mineralization of 1200mg/cm3 to correct for partial volume
effects (density weighted cortical thickness [Ct.Th.DW]).
In addition to the cortex, a trabecular region was deﬁned by
removing the cortex and the outer 2mm of the remaining
vertebral body to avoid endosteal subcortical bone of higher
density (Fig. 1G, H). A second elliptical trabecular region was
evaluated (Fig. 1F), very similar to the elliptical region used onQCT
images (Fig. 1E), and BMDwas measured for both trabecular VOIs.
For microstructural characterization of the trabecular regions
apparent bone volume fraction (app.BV/TV) and apparent
trabecular separation (app.Tb.Sp) were assessed by binarization
with a ﬁxed, predeﬁned threshold of 250mg/cm3.(7) App.Tb.Sp
was deﬁned as the median length of all sections within the
background (marrow) of the search grid of the directed secant
method.(22) This approach was also used to calculate apparent
trabecular number (app.Tb.N) as total number of intersection per
total test length. App. BV/TV and app.Tb.N were used to derive
apparent bone surface‐to‐volume ratio (app.BS/BV) as 2 [app.Tb.
N]/[app.BV/TV]. Trabecular TMD could be calculated from BMD/
[BV/TV] but for the trabecular compartment result will be even
more heavily affected by partial volume effects. Therefore, we did
not include this in the set of variables to be evaluated statistically.
Still, interpretation of relative changes under treatment may
provide useful insights and are helpful in the context of the
discussion of the results. The preﬁx “app.” was added to standard
nomenclature of structural variables to indicate the inﬂuence of
limited resolution and signal‐to‐noise ratio.(7)
FE analysis
Digital FE models were generated for each patient and for each
HRQCT time point from the segmented HRQCT images at an
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isometric resolution of 1.3mm. The superior and inferior
endplates were embedded in a virtual thin layer of polyme-
thylmethacrylate and the mineral density of each voxel/element
was converted to bone volume fraction (BV/TV) with a calibration
equation assuming a homogeneous normal tissue density. The
bone tissuematerial behavior was elasto‐plastic with damage; ie,
irreversible strain ﬂow and elastic modulus decrease with
postyield loading history. The model generation procedure
and bone material properties have been described in detail by
Chevalier and colleagues.(23) In order to account for a broad
spectrum of physiological loading, FE analysis of each vertebral
body included axial compression, anterior bending, and axial
torsion.(24) The structural output variables were stiffness (kN/mm)
and maximal load (kN) for axial compression, and angular
stiffness (kNmm/rad) and maximal torque (kN/mm) for anterior
bending and axial torsion. A normalized strength in axial
compression (N/mm2¼MPa) was calculated as strength divided
by the central cross‐sectional area of the vertebral body.(25)
DXA
Lumbar spine (L1–L4), total hip, and femoral neck aBMD were
measured by DXA. aBMD results of the total hip obtained on
Hologic, GE‐Lunar, and Norland scanners were converted to
standardized values, and aBMD results of the lumbar spine and
femoral neck obtained on Lunar and Norland scanners were
converted to Hologic values using published and validated
formulas.(26,27) All DXA instruments used in the trial were
standardized and cross‐calibrated through the use of an
anthropomorphic spine phantom (Bona Fide Phantom [BFP],
BioImaging Technologies, Leiden, The Netherlands).
Biochemical markers of bone turnover
Serum concentrations of P1NP and b‐CTx were determined at
baseline, 3, 6, and 18 months of treatment. Serum samples were
prepared and stored at –20°C or lower at the study site and sent
to the central laboratory for processing. All samples from an
individual were assayed in a single analytical batch. Serum P1NP
was measured by the Intact UniQ RIA assay (Orion Diagnostica,
Espoo, Finland). The interassay (within day) analytical coefﬁcient
of variation (CV) was 3.1% to 8.2% over the reference interval.
Serum b‐CTx was measured by the serum Crosslaps Enzyme
Linked Immunosorbent Assay (Nordic Bioscience Diagnostics,
Herlev, Denmark).The interassay CV was 5.4% to 11.4%.
Safety measures
Safetymeasures included pre‐existing conditions and treatment‐
emergent adverse event (TEAEs), physical examination, body
weight, height, and body mass index (BMI), vital signs, new
Fig. 1. 2D and 3D visualization of a vertebra imaged noninvasively by high‐resolution quantitative computed tomography. The 3D images of the top row
show a vertebra viewed from two angles differing by 180 degrees (A, B versus C, D). The semitransparent versions (B, D) depict the cortical endplates and
elements of the trabecular microstructure of a selected subvolume (colored brown within the semitransparent vertebral body). The bottom row shows
placement of the volume of interest (VOI) within the vertebral body in the axial (E–G) and sagittal (H) planes. For HRQCT (F–H) a cortical region (endplates
and lateral and anterior cortices depicted on G and H) and two different trabecular regions (elliptical in F and entire volume in G and H), except a 2‐mm
subcortical endosteal region, were evaluated. The elliptical region in Fwas deﬁned similar to the standard QCT region shown, for comparison, on a regular
resolution QCT image in E. Compared to QCT, HRQCT demonstrates improved delineation of cortical bone (E versus F).
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clinical fractures, and hypercalcemia deﬁned as a serum calcium
level corrected for albumin of >2.7mmol/L (>10.8mg/dL).
Statistical analysis
It was estimated that a sample size of 31 subjects in each group
would give at least 85% power to detect a between‐treatment
difference in the mean change of BMD from baseline to
18 months of 11.25 g/cm3, assuming a common SD of 15 g/cm3.
This was based on a two‐sample t test at the 5% signiﬁcance. In
the preplanned primary analysis, a mixed‐model repeated
measures (MMRM) model was evaluated for the change from
baseline in lumbar spine trabecular BMD. The same MMRM
model was applied to secondary efﬁcacy data.
The prespeciﬁed primary MMRM model (“full model”) for
change from baseline in the different primary and secondary
efﬁcacy endpoints included ﬁxed effects for treatment, visit,
interaction between treatment and visit, baseline result of the
respective diagnostic variable, age, baseline P1NP, fracture
within 12 months prior to study (yes/no), duration of prior
bisphosphonate use, baseline GC dose and cumulative GC doses
before and during the study, and patient nested within
treatment (as random effect). The primary comparison between
treatments was assessed at 18 months and, as part of the
secondary analysis, at 6 months. Within treatments, the least
square (LS) mean changes (given also as percentage changes
from baseline) with standard errors and p values were analyzed
and reported at 6 and 18 months.
To assess the relevance of the baseline adjustments, and as
supportive analyses, a “reduced”MMRMmodel with ﬁxed effects
for treatment, visit, the interaction between treatment and visit,
and baseline value of the respective diagnostic variable was also
applied on the primary and secondary efﬁcacy measures. To
maintain the dataset of the full model, patients withmissing data
on confounders of the full model were excluded in the reduced
model. In addition, changes from baseline to endpoint within
treatment groups were tested with t tests and nonparametric
Wilcoxon tests with last observation carried forward (LOCF)
applied to patients with missing observations at month 18.
Efﬁcacy analyses were based on the full analysis set (FAS),
which included all randomized patients who received at least 1
dose of study medication. Observations included in the MMRM
model were limited to those that had nonmissing values for the
change in the diagnostic variable studied, and nonmissing values
for all of the confounders. To be included in the primary efﬁcacy
analysis, FAS patients also needed to have a trabecular BMD
measurement by QCT at baseline and at least one postbaseline
visit; similarly, a measurement of the secondary endpoints at
baseline and at least one postbaseline measurement for the
variable assessed were required for inclusion in the secondary
efﬁcacy analysis datasets. Conﬁrmatory efﬁcacy analyses were
performed using the per‐protocol population that excluded any
pre‐deﬁnedmajor protocol violators. The safety analysis set used
for safety analyses included all patients who received study
treatment, and patients were analyzed as treated.
Patients with TEAEs and new clinical fractures were compared
between treatments using Fisher’s exact test. In addition, the
number of clinical fractures was compared in a post hoc analysis
using a Poisson regression including treatment as independent
variable.
All statistical tests were conducted two‐sided at the 5%
signiﬁcance level and no multiplicity adjustments were
performed for secondary endpoints. Data were analyzed using
SAS software version 9.2 (SAS Institute, Inc., Cary, NC).
Results
A total of 174 patients were screened at 19 study sites. Of these
patients, 92 were eligible and randomly assigned to teriparatide
(45 patients) or risedronate (47 patients) (Fig. 2). A total of 15
patients discontinued the study prematurely, 7 (15.6%) in the
teriparatide group and 8 (17.0%) in the risedronate group.
Patients’ baseline characteristics were generally balanced
between treatment groups, with the exception of a higher
frequency of anti‐tumor necrosis factor (TNF) therapy in the
risedronate group (Table 1). Mean age was 56.3 years (range, 25–
82 years). In both study groups combined, 36 patients (39.1%)
Fig. 2. Patient disposition. HRQCT¼high resolution quantitative computed tomography; N¼ total number of patients; QCT¼quantitative computed
tomography. aThree patients with missing data for covariates included in the full MMRM model (1 teriparatide and 2 risedronate patients).
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Table 1. Baseline Characteristics
Variable Teriparatide Risedronate Total
Age (years)
n 45 47 92
Mean (SD) 57.5 (12.8) 55.1 (15.5) 56.3 (14.2)
Race: Caucasian, n (%) 44 (97.8) 46 (97.9) 90 (97.8)
Anthropometry
n 45 47 92
Body mass index (kg/m2), mean (SD) 27.2 (5.0) 26.5 (4.2) 26.9 (4.6)
Height (cm), mean (SD) 172.2 (7.8) 170.0 (9.7) 171.1 (8.8)
Weight (kg), mean (SD) 80.9 (16.7) 76.8 (14.1) 78.8 (15.5)
Patients with 1 previous osteoporosis therapy, n (%) 14 (31.1) 17 (36.2) 31 (33.7)
Any bisphosphonate 14 (31.1) 16 (34.0) 30 (32.6)
Duration of prior bisphosphonate use (months)
n 13 16 29
Median (Q1, Q3) 4.0 (2.0, 5.0) 4.5 (2.0, 23.5) 4.0 (2.0, 22.0)
Patients with 1 previous anti‐TNF therapy, n (%) 5 (11.1) 10 (21.3) 15 (16.3)
aBMD (by DXA)
n 45 47 92
Lumbar spine (T‐score) –2.48 (1.01) –2.33 (1.19) –2.40 (1.11)
Total hip (T‐score) –1.64 (0.87) –1.51 (0.90) –1.57 (0.88)
Femoral neck (T‐score) –1.95 (0.78) –1.82 (0.91) –1.88 (0.85)
BMD (by QCT)
n 39 40 79
Lumbar spine L1–L3 (mg/cm
3) 75.7 (28.8) 78.2 (29.5) 77.0 (29.0)
Prevalent fracturesa
n 45 47 92
Subjects with 1 fracture(s) prior to study, n (%) 19 (42.2) 17 (36.2) 36 (39.1)
Fracture <12 months before study, n (%) 4 (8.9) 4 (8.5) 8 (8.7)
Number of fractures per patientb
Mean (SD) 1.8 (0.96) 2.0 (1.22) 1.9 (1.08)
Time since last fracture (months)
Median (Q1, Q3) 27.8 (15.3, 106.0) 44.9 (10.4, 91.6) 31.5 (10.4, 91.6)
Patients with vertebral fractures, n (%) 15 (42.9) 18 (52.9) 33 (47.8)
Patients with nonvertebral fractures, n (%) 20 (57.1) 16 (47.1) 36 (52.2)
SDI
n 44 45 89
Mean (SD) 1.7 (2.9) 1.0 (1.5) 1.3 (2.3)
Hormonal and bone markers
25‐Hydroxy vitamin D (pmol/mL)
n 45 46 91
Mean (SD) 64.6 (23.7) 55.0 (29.0) 59.7 (26.8)
Serum PTH (1–84) (pmol/L)
n 45 47 92
Mean (SD) 3.6 (1.07) 3.7 (1.56) 3.6 (1.34)
Total testosterone (ng/dL)
n 32 31 63
Mean (SD) 432.0 (153.8) 416.9 (187.4) 424.5 (169.9)
b‐CTx (ng/mL)
n 42 47 89
Mean (SD) 0.4 (0.18) 0.4 (0.22) 0.4 (0.20)
P1NP (µg/L)
n 42 47 89
Mean (SD) 31.7 (22.9) 34.6 (20.1) 33.2 (21.4)
n¼number of patients with available data; Q1¼ lower quartile; Q3¼upper quartile; TNF¼ tumor necrosis factor; aBMD¼ areal bone mineral density;
DXA¼dual‐energy X‐ray absorptiometry; BMD¼bone mineral density; QCT¼quantitative computerized tomography; SDI¼ spinal deformity index;
PTH¼parathyroid hormone; b‐CTx¼ type I collagen degradation fragments; P1NP¼ amino‐terminal propeptide of type I procollagen.
aBetween the age of 21 and study entry.
bPrior to the study, a total of 35 fractures (including 8 [22.9%] due to severe trauma) occurred in the teriparatide group compared to 34 (including 8
[23.9%] due to severe trauma) in the risedronate group.
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had a previous fracture, and 31 patients (33.7%) had received an
osteoporosis therapy prior to the study, mostly bisphosphonates
(Table 1). The median GC dose at baseline was 8.8mg/d, and GCs
weremainly taken for rheumatoid arthritis (22.7% of GC requiring
disorders), Crohn’s disease (14.5%), asthma (10.0%), and chronic
obstructive pulmonary disease (8.2%), for a median duration of
6.4 years (Table 2).
Efficacy findings
QCT analysis
At 18 months, patients in the teriparatide group had asigniﬁcantly greater increase in LS mean ( SE) trabecular
BMD at L1–L3 from baseline than patients in the risedronate
group (12.3 3.2mg/cm3 versus 2.9 3.1mg/cm3; p¼ 0.004)
(Fig. 3). This corresponds to increases of 16.3% 4.2% in the
teriparatide group compared to 3.8% 4.1% in the risedronate
group (Fig. 3). The between‐treatment differences at 6 months
were not signiﬁcantly different. Results were conﬁrmed in the
analysis based on the reduced MMRMmodel. The increases from
baseline in trabecular BMD were statistically signiﬁcant for the
two treatment groups in the LOCF analysis.
HRQCT analysis
HRQCT results with nonmissing covariates data were available on
a subset of 58 patients (28 on teriparatide, 30 on risedronate). Of
these, 51 (23 on teriparatide, 28 on risedronate) had nonmissing
data at 6 months and 56 subjects (28 on risedronate, 28 on
teriparatide) at 18 months (Fig. 4). HRQCT results from the full
MMRM model for absolute changes from baseline are summa-
rized in Table 3, and percent changes are depicted in Fig. 4 for a
subset of HRQCT variables. Mean changes from baseline to
18months were statistically signiﬁcant for all HRQCT variables for
both treatment groups, with the exception of the change in the
cross‐sectional area of the vertebra in the risedronate group.
Table 2. Previous Glucocorticoid Use
Variable Teriparatide Risedronate Total
Glucocorticoid dose at baseline (mg/d)
n 44 43 87
Median (Q1, Q3) 8.8 (5.0, 15.0) 8.8 (5.0, 12.5) 8.8 (5.0, 15.0)
Glucocorticoid cumulative dose (g)
n 45 47 92
Median (Q1, Q3) 20.0 (8.3, 43.5) 15.3 (4.6, 32.0) 15.8 (6.3, 37.5)
Duration of prior glucocorticoid treatment (years)
n 45 47 92
Median (Q1, Q3) 7.1 (2.3, 13.2) 4.9 (2.5, 12.9) 6.4 (2.4, 13.0)
Underlying glucocorticoid‐requiring disorders, n (%)a
Rheumatoid arthritis 11 (19.0) 14 (26.9) 25 (22.7)
Crohn’s disease 5 (8.6) 11 (21.2) 16 (14.5)
Asthma 8 (13.8) 3 (5.8) 11 (10.0)
Chronic obstructive pulmonary disease 6 (10.3) 3 (5.8) 9 (8.2)
Bronchitis chronic 3 (5.2) 0 3 (2.7)
Systemic lupus erythematosus 3 (5.2) 0 3 (2.7)
Pemphigus 2 (3.4) 1 (1.9) 3 (2.7)
Ankylosing spondylitis 1 (1.7) 2 (3.8) 3 (2.7)
Psoriatic arthropathy 0 3 (5.8) 3 (2.7)
Behçet’s syndrome 1 (1.7) 1 (1.9) 2 (1.8)
n¼number of patients with available data; Q1¼ lower quartile; Q3¼ upper quartile.
aDisorders reported more than once overall; the following disorders were reported once: ulcerative colitis, autoimmune hepatitis, sarcoidosis, giardiasis,
osteoarthritis, polymyalgia rheumatica, myasthenia gravis, allergic alveolitis, idiopathic pulmonary ﬁbrosis, pulmonary ﬁbrosis, and psoriasis.
Fig. 3. Treatment associated changes from baseline for teriparatide
compared to risedronate in lumbar spine (L1–L3) trabecular BMD
measured by QCT. BMD¼bone mineral density; LS¼ least square;
SE¼ standard error. Percentages reﬂect the percent change from
baseline; statistics from a mixed‐model repeated measures analysis
adjusted for predeﬁned variables (full model with nonmissing data for
n¼ 35 and n¼ 37 at month 6, and n¼ 36 and n¼ 34 at month 18 for
teriparatide and risedronate, respectively).
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Similar results were observed for the LOCF analysis (data not
shown). Examples of the treatment effects for teriparatide and
risedronate are visualized in Fig. 5.
HRQCT‐based increases in T12 integral and trabecular BMD
were signiﬁcantly larger for teriparatide compared to risedronate
at 18 months (Table 3, Fig. 4). Among microstructural variables, a
statistically signiﬁcant difference was observed for app.BS/BV
(p¼ 0.032) and app.BV/TV showed a trend (p¼ 0.098), both in
favor of teriparatide (Table 3, Fig. 4). Similar results were
observed in the analysis based on the reduced MMRM model
where the improvements of both, app.BV/TV and app.BS/BV,
were signiﬁcantly larger for teriparatide compared to risedronate
(p¼ 0.045 for both variables). No signiﬁcant differences between
treatments were observed in HRQCT variables at 6 months. All
aforementioned HRQCT results of the trabecular region were
evaluated in the larger VOI encompassing almost all trabecular
bone (Fig. 1G, H). Results from the elliptical subregion (Fig. 1F)
were similar (data not shown).
FE analysis
At 18 months, statistically signiﬁcant increases in vertebral
strength were observed for both treatment groups and all three
loading modes, with statistically signiﬁcant larger increases in
the teriparatide group (Fig. 6). Similar results were observed for
vertebral stiffness, as well as in the LOCF analyses of strength and
stiffness (data not shown). Normalized strength in axial
compression yielded similar results compared to the non‐
normalized strength analysis in the teriparatide‐treated subjects
(26.2% and 26.0% respectively), whereas it showed slightly
higher values in the risedronate group (5.8% and 4.2%,
respectively), the difference between treatments remained
signiﬁcant (p¼ 0.021). Between‐treatment differences were not
statistically signiﬁcant at month 6. Results from the reduced
MMRM model were comparable with those from the full MMRM
model.
Biochemical markers of bone turnover
The course over time of median percentage changes from
baseline for biochemical markers of bone turnover (P1NP and b‐
CTx) are depicted in Fig. 7. Differences between treatments in the
change from baseline were statistically signiﬁcant at all time
Fig. 4. Treatmentassociatedpercentchanges frombaselineto18months
(LSmeanþ SE) for teriparatide compared to risedronate in T12 BMD, bone
microstructure, and one variable affected by density and microstructure
(density‐weighted cortical thickness), all measured by HRQCT.
BMD¼bone mineral density; BS/BV¼bone surface to volume ratio; BV/
TV¼bone volume fraction; Ct.BMD¼ cortical BMD; Ct.Th.DW¼density
weighted cortical thickness; HRQCT¼high resolution quantitative
computed tomography; Int.BMD¼ integral BMD; Integr.¼ integral;
T12¼ 12th thoracic vertebra; LS¼ least square; SE¼ standard error; Tb.
BMD¼ trabecular BMD; Tb.N¼ trabecular number; Trab.¼ trabecular.
Percent change from baseline from a mixed‐model repeated measures
analysis adjusted for predeﬁned variables (full model with nonmissing
data for n¼ 28 and n¼ 30 at month 18 for teriparatide and risedronate,
respectively). For BS/BV more negative values represent improvement.
Table 3. Changes From Baseline to Month 18 in High‐Resolution Quantitative Computed Tomography of T12
Time point
Teriparatide (n¼ 28) Risedronate (n¼ 30)
Treatment
difference (p)Baseline
LS mean
change SE Baseline
LS mean
change SE
Integral BMD (mg/cm3) 105.0 15.24 4.86 102.0 4.16 5.34 0.028
Trabecular bone BMD (mg/cm3) 87.3 12.62 4.14 83.7 1.64 4.57 0.011
BMD of cortical VOI (mg/cm3) 287 22.89 5.18 291 17.73 5.54 0.328
Apparent BS/BV (mm) 7.75 –0.31 0.14 8.08 –0.00 0.15 0.032
Apparent BV/TV 0.13 0.029 0.009 0.12 0.013 0.010 0.098
Apparent trabecular number per area (1/mm) 0.47 0.07 0.02 0.44 0.06 0.02 0.509
Apparent trabecular separation (mm) 4.25 –0.83 0.25 3.93 –0.65 0.26 0.500
Cortical thickness (mm) 2.06 –0.14 0.03 2.01 –0.17 0.03 0.270
Cortical thickness weighted by BMD (mm) 0.25 0.02 0.01 0.25 0.01 0.01 0.240
Cross‐sectional area, central slice (mm2) 1154 9.82 3.87 1140 7.07 4.17 0.507
Signiﬁcance of treatment differences derived from the full mixed‐model repeated measures analysis adjusted for predeﬁned variables. Bold indicates
signiﬁcant values of p.
n¼number of patients; T12¼ 12th thoracic vertebra; LS¼ least squares; BMD¼bone mineral density; VOI¼ volume of interest; BS¼bone surface;
TV¼ tissue volume; BV¼bone volume.
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points (p< 0.001) with the exception of b‐CTx at month 18
(p¼ 0.105). As expected, in the teriparatide group, P1NP and b‐
CTxwere increased at 3months and peaked at 6months (median
increase from baseline of 175.7% [P1NP] and 72.2% [b‐CTx]). In
the risedronate group, these markers decreased at 3 months and
remained suppressed at 18 months (Fig. 7). Between‐treatment
test results from the reduced model were similar to those from
the full model.
Fig. 5. 3D visualization of treatment effect for 2 representative patients. BMD¼bone mineral density; BV/TV¼bone volume fraction; TMD¼ tissue
mineral density. Treatment with teriparatide resulted in a visible increase in bone volume, whereas under risedronate maintenance of bone structure was
observed. Bone mineral density increased for both patients. Tissue mineral density was reduced under teriparatide (reﬂecting apposition of not yet fully
mineralized bone) whereas it increased under risedronate due to reduction of bone turnover.
Fig. 6. Treatment associated percent changes from baseline (LS meanþ SE) in vertebral strength of T12 for teriparatide compared to risedronate as
modeled by ﬁnite element analysis based on high‐resolution quantitative computed tomography; results for three loading modes (top right). LS¼ least
square; SE¼ standard error; T12¼ 12th thoracic vertebra. Statistics from amixed‐model repeatedmeasures analysis adjusted for predeﬁned variables (full
model with nonmissing data for n¼ 23 and n¼ 28 at month 6, and n¼ 28 and n¼ 28 at month 18 for teriparatide and risedronate, respectively). Within
groups, the increases from baseline in the LOCF analysis were statistically signiﬁcant for the two treatment groups (p< 0.001).
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DXA analysis
After 18 months of treatment, aBMD at the lumbar spine and the
total hip signiﬁcantly increased from baseline for both groups
(p< 0.05). Changes were statistically signiﬁcantly higher for
teriparatide at the lumbar spine (LS mean SE: 0.060 0.015 g/
cm2 for teriparatide [þ6.94%] versus 0.030 0.015 g/cm2 for
risedronate [þ3.33%]; p¼ 0.045), and at the femoral neck (0.011
 0.009 g/cm2 for teriparatide [þ1.52%] versus 0.009
 0.009 g/cm2 for risedronate [–1.10%]; p¼ 0.026) (Fig. 8).
However, between group differences were not signiﬁcant at
the total hip (0.017 0.008 g/cm2 for teriparatide [þ2.07%]
versus 0.008 0.008 g/cm2 for risedronate [þ0.99%]; p¼ 0.256).
For the primary and secondary efﬁcacy endpoints, results
based on the per protocol population, which excluded 16
patients (9 in the teriparatide and 7 in the risedronate group)
because of major predeﬁned protocol violations, were compara-
ble to those from the full analysis data sets. Similarly, a post hoc
analysis that included the underlying disorder category as a
covariate in the fully adjusted model showed almost identical
results to the predeﬁned model.
Safety and tolerability findings
In the teriparatide group, the median (lower quartile [Q1], upper
quartile [Q3]) duration of GC therapy during the study was 17.8
months (16.1, 18.0 months), and the median (Q1, Q3) cumulative
GC dose was 4.1 g (2.7, 5.6 g). Patients in the risedronate group
took GCs for a median (Q1, Q3) duration of 17.5 months (8.9, 18.0
months; p¼ 0.341 compared to teriparatide), with a median (Q1,
Q3) cumulative GC dose of 3.1 g (2.4, 5.9 g; p¼ 0.376).
Fewer patients in the teriparatide group than in the
risedronate group reported TEAEs or SAEs (Table 4); however,
between‐treatment differences were not statistically signiﬁcant
(p¼ 0.080 and p¼ 0.089, respectively). None of the patients in
the teriparatide group compared to 5 patients (10.6%) in the
risedronate group had a new clinical fracture during the study
(p¼ 0.056). The 5 patients in the risedronate group had a total of
11 clinical fractures: eight rib fractures and one fracture each at
the hip, radius, and ankle (p< 0.001 between‐treatment analysis
from Poisson regression). No clinical vertebral fractures were
reported during the study. No cases of hypercalcemia were
reported and no clinically relevant ﬁndings were seen in the
assessment of vital signs, height, weight, and BMI.
Discussion
GIO can have devastating sequels with high rates of morbidity
and mortality after a fracture, and signiﬁcant cost to society with
respect to hospital expenses and loss of independence from
related complications, in the context of an already debilitating
underlying disorder.(28)
In this active‐comparator trial of men with GIO, daily
subcutaneous teriparatide was more efﬁcacious than weekly
oral risedronate to increase BMD at the lumbar spine measured
by QCT at 18 months of treatment, which was the maximum
treatment duration approved in the participating countries at the
time the study was conducted. Moreover, teriparatide‐treated
patients appeared to show additional signiﬁcant skeletal beneﬁts
compared to risedronate‐treated patients, with greater improve-
ments in bone strength and stiffness, as calculated by HRQCT‐
based FE analysis at the 12th thoracic vertebra. Such improve-
ments were shown for strength under compressive and bending
loads, as well as under axial torsion. HRQCT analysis revealed
greater increases in integral and trabecular BMD with teripara-
tide, without signiﬁcant differences in cortical BMD between the
two treatment groups. With the only exception of cross‐sectional
area of the vertebral body, all other structural variables derived
from HRQCT analysis showed statistically signiﬁcant increases
from baseline for both treatment groups. For all microstructural
Fig. 7. Temporal changes in bone formation (P1NP) and bone resorption
(b‐CTx) markers; *p< 0.001 for the between‐treatment comparison
based onmixed‐model repeatedmeasures analysis adjusted for selected
variables (full model).
Fig. 8. Percent changes in areal BMD measured by DXA between
baseline and month 18. BMD¼bone mineral density; LS¼ least square;
SE¼ standard error. Note: p values from a mixed‐model repeated
measures analysis adjusted for selected variables (full model).
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variables, the improvement was somewhat larger for teriparatide
compared to risedronate, but only for BS/BV the between‐
treatment difference reached statistical signiﬁcance. In the full
model, bone volume fraction (BV/TV) showed a trend for greater
increase in the teriparatide group (p¼ 0.098), and was statisti-
cally signiﬁcant in the reduced MMRM model (p¼ 0.045).
The assessment of the bone structure and BMD by volumetric
QCT and HRQCT at axial fracture sites, such as the spine, with
improved spatial resolution and faster scan acquisition empow-
ered by multidetector technology and spiral scanning, allows a
differentiated analysis of the different bone compartments, and
more accurately reﬂects the skeletal effects of bone active drugs
than conventional DXA. DXA has the disadvantage of being
based on a 2D assessment of a 3D structure with resulting bias of
the measured aBMD caused by degenerative disorders. 3D
imaging modalities provide a better estimation of bone strength
at the spine level using FE analysis,(23,25) as well as better
prediction of vertebral fracture risk in men.(29)
The results of this trial in men with GIO are similar to previous
results in postmenopausal women with osteoporosis where
trabecular BMD at the spine, measured with the same QCT
software, showed an increase of 19.0% and 3.8% after 18months
of teriparatide and daily alendronate, respectively.(30) Similar
QCT‐based responses to teriparatide have been reported from
other studies in postmenopausal women.(14,31) Of note, in a study
in postmenopausal women with severe GIO who received
therapy with a daily teriparatide dose of 25 µg combined with
hormone replacement therapy for 12 months, the BMD increase
at L1–L2 was substantially higher (35%).
(32) Similarly, in a 2‐year
comparator trial in men with non‐GC–associated low bone mass,
treatment with teriparatide (37 µg/d) increased trabecular BMD
of L1–L4 by 48% compared with 3% in the alendronate daily
group.(18) However, it should be noted that these two latter
studies used older QCT software, and therapy was with higher
doses of synthetic, non‐recombinant teriparatide than in the
more recent studies.
This is the ﬁrst study in which HRQCT was used to study not
only bone forming(7,14) but also antiresorptive treatment. A post
hoc sensitivity test comparing QCT and HRQCT on the largest
common dataset (n¼ 55 at 18 months) conﬁrmed that the
discriminatory power of HRQCT for differentiating treatment
effects based on trabecular BMD was at least as large as that of
QCT (p< 0.01 versus p< 0.05, respectively).
The higher spatial resolution of HRQCT permits more detailed
insight into compartment‐speciﬁc changes in microstructure,
but for interpretation of results, the limits of resolution, ie, partial
volume effects, need to be considered.(21) Teriparatide can be
expected to lead to increases in BV/TV, but since the newly added
bone matrix is not yet fully mineralized, the magnitude of
increases may be underestimated as a consequence of partial
volume effects. For risedronate the opposite effect can be
expected: increases in TMD may lead to a virtual increase in BV/
TV. As a consequence, the difference in treatment effects on BV/
TV will be underestimated. Second, although BMD data were
cross‐calibrated across centers, no such procedure has been
implemented yet for measurements of microstructure. Differ-
ences between scanners and reconstruction kernels can be
substantial, and development of cross‐calibration procedures
Table 4. Summary of TEAEs
Preferred term
Number (%) of patients
paTeriparatide (n¼ 45) Risedronate (n¼ 47)
Number of patients with 1 TEAE 25 (55.6) 35 (74.5) 0.080
Reported in >4% of patients overall
Arthralgia 4 (8.9) 3 (6.4)
Influenza 4 (8.9) 3 (6.4)
Edema peripheral 3 (6.7) 2 (4.3)
Chronic obstructive pulmonary disease (exacerbation) 2 (4.4) 4 (8.5)
Nasopharyngitis 2 (4.4) 2 (4.3)
Dyspnea 1 (2.2) 3 (6.4)
Fall 1 (2.2) 3 (6.4)
Nausea 1 (2.2) 3 (6.4)
Weight increased 1 (2.2) 3 (6.4)
Number of patients with 1 SAE 13 (28.9) 22 (46.8) 0.089
Reported in >2% of patients overall:
Intervertebral disc protrusion 3 (6.7) 0
Chronic obstructive pulmonary disease 2 (4.4) 3 (6.4)
Crohn’s disease (exacerbation) 0 2 (4.3)
Fall 0 2 (4.3)
Hypertensive crisis 0 2 (4.3)
Death 2 (4.4) 1 (2.1) 0.613
Number of discontinuations due to TEAE 0 3 (6.4) 0.242
TEAE¼ treatment‐emergent adverse event; SAE¼ serious adverse event.
ap value from Fisher’s exact test.
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under way should improve microstructural assessment in a
multicenter setting. Despite these conditions and the smaller
sample size of HRQCT data, we were able to differentiate
structural treatment effects based on app.BS/BV. Apparently, the
partial volume–related bias of app.Tb.N and app.BV/TV largely
cancelled out for app.BS/BV, which was calculated from the ratio
of these two measures. As would be expected for an
antiresorptive agent, no changes were observed for app.BS/BV
for risedronate, whereas app.BS/BV was reduced (ie, improved)
for teriparatide, in line with the expected effect of bone
apposition. Between‐treatment differences in BV/TV were
borderline signiﬁcant, depending on the MMRM model (full or
reduced) selected. One should note that this was achieved
despite the fact that BV/TV was measured directly as a true
microstructural measure, and was not simply derived from BMD
as is done with the Xtreme‐CT device for peripheral HRQCT.(33)
The latter, by deﬁnition, cannot yield independent structural
information.
Given the limited spatial resolution, for cortical bone structure
we considered it to be difﬁcult to separate treatment effects on
thickness from effects on TMD. To maximize sensitivity of a
cortical measure, we derived Ct.Th.DW, which reﬂects the
combined effect on both thickness and density. As a conse-
quence, we succeeded in picking up treatment effects for both
treatments but at the expense of being unable to differentiate
bone forming effects of endosteal apposition (for teriparatide)
from increases in TMD (for risedronate). Modiﬁcations of cortical
measures are under development.
QCT‐based FE analysis incorporates vertebral geometry, BMD
distribution, and impacting loads to estimate vertebral strength.
Microstructural changes such as trabecular thinning, lower BV/
TV, and reduced connectivity have been reported for GIO based
on histological data(34–36) or micro‐CT analysis.(36) However, to
date, it has not been possible to measure these aspects
noninvasively in humans.(9) The publication by Ito and
colleagues(6) conﬁrmed the potential of QCT approaches for
assessing vertebral microstructure in vivo. Our HRQCT‐based FE
results document that there is a stronger effect of teriparatide
compared to risedronate on the biomechanical properties of the
vertebra in men with GIO after 18 months of treatment. The FE
methodology used in this study has been validated by showing
that it provides predictions of vertebral maximum load that
correlate well with ex vivo human vertebral sections tested
mechanically in axial compression.(23) In this study, we observed
highly consistent results for axial compression, anterior bending,
and axial torsion, the latter being investigated in a clinical study
for the ﬁrst time. Of note, the improvements in vertebral strength
were similar regardless of the loading mode for both drugs.
Similarly, the axial compression strength analysis normalized by
the vertebral body cross‐sectional area did not show major
differences with the non‐normalized measurement. FE methods
could be further reﬁned by ﬁner meshing and incorporation of
microstructural data from HRQCT.
In general, the strength results observed in this study were
very similar to the FE analysis carried out in postmenopausal
osteoporosis in the teriparatide and alendronate comparator
trial,(13) and the OPTAMISE study.(16) As it was shown in
postmenopausal women treated with alendronate,(13) the
biomechanical response to risedronate stagnates after 6 months
of therapy, whereas anabolic treatment leads to a further
improvement with the additional 12 months of therapy. In fact,
extended treatment durations with teriparatide to up to
24 months are associated with substantial increases in the
maximum load at the spine of postmenopausal women with
severe osteoporosis who had previously been treated with
antiresorptive drugs.(14)
Based on the observed differences in BMD and the observed
biomechanical responses, teriparatide treatment might be
expected to provide better fracture risk reduction beneﬁts in
men with GIO. However, this could not be ascertained as this
study was not primarily designed to compare incident fracture
differences. A trend (p¼ 0.056) in the number of patients with
new clinical fractures was observed in favor of teriparatide,
where no new clinical fractures were reported in the teriparatide
group whereas 5 patients in the risedronate group reported a
total of 11 nonvertebral fractures. In a recent clinical trial in
patients with GIO, Saag and colleagues(37) showed that
signiﬁcantly fewer subjects had new vertebral fractures in the
teriparatide group compared with the alendronate group (0.6%
versus 6.1%, respectively), whereas the incidence of nonvertebral
fractures was similar in both groups (5.6% versus 3.7%).
The changes in areal DXA and the response of the biochemical
markers of bone turnover were expected, with greater increases
in lumbar spine and femoral neck aBMD after 18 months in the
teriparatide group, which conﬁrms previous results from a
subgroup analysis of 74 men with GIO treated with alendronate
or teriparatide.(38) It also conﬁrms previous reports in patients
with GIO, where early increases in bone formation and resorption
markers in the teriparatide group compared with a reduction of
bone turnover with alendronate were shown,(37–39) which
reﬂects the differing mechanisms of action of bone forming
and antiresorptive drugs.(40) There were no unexpected or
disconcerting safety ﬁndings for either treatment, and both
drugs were generally well tolerated.
Our study has several limitations. Due to more frequent
violations of the HRQCT scan protocol, the number of valid
postbaseline HRQCT evaluations was smaller compared with the
QCT analyzed cases, which negatively impacted the statistical
power to show differences between the study groups in HRQCT
structural variables. A limitation of the FE analysis is that bone
tissue properties are assumed to be constant for all patients and
over the course of pharmacological treatment.(41) Treatment
modiﬁes the average level TMD, and for GIO it is known that
fracture risk at a given level of BMD is higher compared to
primary postmenopausal osteoporosis(42) moreover, the rapid
onset of fractures after initiation of treatment and the similarly
rapid return to pretreatment levels of fracture risk after
termination of treatment(43) cannot be explained by changes
in BMD alone. However, the magnitude of these effects remains
unclear and further reﬁnement of HRQCT may help to address
this issue. Another limitation of the study is that the duration of
treatment was for 18 months only. Longer treatment may offer
even more pronounced advantages.(44,45) The imbalance in anti‐
TNF use between groups at baseline may reﬂect the distribution
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of underlying disorders between groups, with subjects in the
risedronate group more frequently reporting musculoskeletal
and gastrointestinal disorders than subjects in the teriparatide
group. However, a post hoc analysis that included the underlying
disorder category as a covariate in the fully‐adjusted model
showed almost identical results to the predeﬁned model.
Our study also has speciﬁc strengths. We studied men with
GIO, which is a population of osteoporotic patients that have
been scarcely evaluated in clinical trials. In contrast to women
with GIO, who normally report very high rates of rheumatologic
disorders, such as rheumatoid arthritis and polymyalgia
rheumatica, menwith GIO have amore heterogeneous spectrum
of underlying disorders, including a higher prevalence of chronic
respiratory disorders and inﬂammatory bowel diseases. We
applied innovative imaging technology, investigating several
aspects of bone microstructure beyond BMD. Our study also
presents the ﬁrst analysis of men with GIO using FE analysis.
Using HRQCT instead of QCT createdmore accurate FE models of
the human vertebral body. Loading conditions used for assessing
vertebral strength include three simulating models, included
axial torsion, which more comprehensively spans the range of
loading conditions that occur in vertebral fractures in humans.
In summary, in this study of men with GIO, treatment for
18 months with teriparatide—a bone forming drug—was more
efﬁcacious than risedronate—a potent antiresorptive—in im-
proving vertebral bone competence with regard to QCT and
HRQCT‐based trabecular BMD, HRQCT‐based integral BMD, FE‐
derived bone strength, and bone surface‐to‐volume ratio as a
microstructural variable. Both teriparatide and risedronate were
generally well tolerated. Additional studies are needed to
elucidate the clinical consequences of these results, and the
place of advanced radiologic imaging techniques in the
assessment of GIO.
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